

TERMINATION OF WAFERMINE LICENSING AGREEMENT

The Board of Directors (the “**Board**”) of iX Biopharma Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) refers to the announcement made by the Company on 17 November 2023 (the “**Announcement**”). Unless otherwise defined, all capitalised terms herein shall have the same meanings as in the Announcement.

The Board wishes to update shareholders that following the provision of the Termination Notice to the Licensee, the Company has issued a follow-up letter in writing to the Licensee to terminate the License Agreement in accordance with the terms of the said agreement. The termination of the License Agreement is not expected to have a material financial impact on the Group.

BY ORDER OF THE BOARD

Eddy Lee
Chairman & CEO

1 March 2024

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #0101, Singapore 229957, telephone (65) 6590 6881.